Background
Methods
Subjects and groups
Patients with asthma (n = 95) | Control subjects (n = 99) | P value | |
---|---|---|---|
Sex (M/F) | 54/41 | 64/35 | 0.266 |
Age (years, mean ± SD) | 28.2 ± 15.8 | 29.1 ± 13.9 | 0.680 |
Attack once a week or a day (yes/no) | 95/95 | 0/99 | <0.000 |
Sign (wheezing) (yes/no) | 95/95 | 0/99 | <0.000 |
FEV1%Pre | 58.4 ± 18.9 | 96.5 ± 9.8 | <0.001 |
IgE (IU/ml, mean ± SD) | 486.9 ± 595.5 | 75.8 ± 124.9 | <0.001 |
IL-4 (ng/L, mean ± SD) | 31.7 ± 17.1 | 5.1 ± 3.8 | <0.001 |
Determination of anti-Hsp60 and anti-Hsp70
Detection of plasma IgE and IL-4
Statistical analyses
Results
Presence of anti-Hsp60 and anti-Hsp70 in plasma
Titers | Patients with asthma (n = 95) | Control subjects (n = 99) | P value | |
---|---|---|---|---|
n (%) | n (%) | |||
Anti-Hsp60 | 1:10 | 17 (17.9) | 5 (5.1) | 0.001 |
1:20 | 8 (8.4) | 1 (1.0) | 0.014 | |
1:40 | 5 (5.3) | 0 (0.0) | 0.027 | |
1:80 | 5 (5.3) | 0 (0.0) | 0.027 | |
Anti-Hsp70 | 1:10 | 32 (33.7) | 8 (8.1) | <0.001 |
1:20 | 19 (20.0) | 4 (4.0) | <0.001 | |
1:40 | 13 (13.7) | 1 (1.0) | <0.001 | |
1:80 | 9 (9.5) | 0 (0.0) | 0.001 | |
Anti-Hsps* | 1:10 | 37 (38.9) | 9 (9.1) | <0.001 |
Association between anti-Hsp60 and anti-Hsp70 with risk for asthma
Variables* | Adjusted Regression coefficient | Standard error | χ2 Value | P value | OR (95% CI)** |
---|---|---|---|---|---|
Constant | -0.977 | 0.509 | 3.676 | 0.055 | |
Sex | 0.392 | 0.318 | 1.519 | 0.218 | 1.48 (0.79~2.76) |
Age | 0.017 | 0.109 | 0.026 | 0.872 | 1.02 (0.82~1.26) |
Family history | 0.602 | 0.219 | 8.215 | 0.085 | 2.01 (1.25~3.25) |
Anti-Hsp60 | 0.459 | 0.328 | 1.965 | 0.161 | 1.58 (0.83~3.01) |
Anti-Hsp70 | 0.794 | 0.248 | 10.224 | 0.001 | 2.21 (1.35~3.59) |
Correlation of anti-Hsp60 and anti-Hsp70 with the severity of asthma
Symptom Severity | No. | Anti-Hsp70 No. (%) | Anti-Hsp60 No. (%) | ||||||
---|---|---|---|---|---|---|---|---|---|
1:10 | 1:20 | 1:40 | 1:80 | 1:10 | 1:20 | 1:40 | 1:80 | ||
Step1: intermittent | 30 | 2 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Step2: mild persistent | 36 | 10 (27.8) | 5 (13.9) | 2 (5.6) | 1 (2.8) | 3 (8.3) | 1 (2.8) | 1 (2.8) | 1 (2.8) |
Step3&4 moderate & severe persistent** | 29 | 20 (69.0) | 14 (48.3) | 11 (37.9) | 8 27.6) | 14 (48.3) | 5 (17.2) | 4 (14.0) | 4 (14.0) |
R value* | 0.809 | 0.958 | 0.968 | 0.959 | 0.954 | 0.864 | 0.947 | 0.947 | |
P value* | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.016 | 0.016 |
Differences in the levels of IgE and IL-4 between asthma patients with positive and negative anti-Hsps
Anti-Hsps(+) (n = 37) | Anti-Hsps(-) (n = 58) | P value | |
---|---|---|---|
Sex (M/F) | 23/14 | 31/27 | 0.403 |
Age (years, mean ± SD) | 25.6 ± 15.6 | 29.3 ± 15.7 | 0.249 |
Family history (yes/no) | 18/19 | 8/50 | <0.001 |
IgE (IU/ml, mean ± SD) | 758.2 ± 685.3 | 313.9 ± 458.2 | 0.001 |
IL-4 (ng/L, mean ± SD) | 36.9 ± 17.2 | 28.5 ± 16.3 | 0.019 |
IgE | IL-4 | Anti-Hsp70 | Anti-Hsp60 | Anti-Hsps | ||||||
---|---|---|---|---|---|---|---|---|---|---|
r
|
P
|
r
|
P
|
r
|
P
|
r
|
P
|
r
|
P
| |
IL-4 | 0.701 | <0.001 | ||||||||
Anti-Hsp70 | 0.369 | <0.001 | 0.222 | 0.010 | ||||||
Anti-Hsp60 | 0.262 | 0.010 | 0.259 | 0.011 | 0.485 | <0.001 | ||||
Anti-Hsps | 0.366 | <0.001 | 0.241 | 0.019 | 0.534 | <0.001 | 0.814 | <0.001 | ||
Asthma severity | 0.330 | 0.001 | 0.236 | 0.022 | 0.461 | <0.001 | 0.538 | <0.001 | 0.417 | <0.001 |